Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC

Core Points - Vincerx Pharma, Inc. intends to file a Form 25 Notification of Delisting with the SEC, which will remove its common stock from Nasdaq [1][3] - Nasdaq issued a Delisting Notice to Vincerx due to non-compliance with the minimum bid price requirement of $1.00 per share for 30 consecutive business days [2] - The company's board has decided to dissolve and liquidate its business, distributing remaining assets to stockholders after settling debts [3] Summary by Sections Delisting and Trading Suspension - Vincerx's common stock will be permanently suspended from trading by Nasdaq at the opening of business on April 23, 2025, following a temporary suspension on April 16, 2025 [1][4] - The company is not eligible for a compliance period and will not appeal Nasdaq's determination [2][3] Company Actions - Vincerx plans to file a Form 25 to delist and deregister its common stock, followed by a Form 15 with the SEC once the delisting becomes effective [3][4] - The company does not intend to seek listing on another national securities exchange [3] Company Background - Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, with a research facility in Monheim, Germany [5]